General
Preferred name
MOMETASONE FUROATE
Synonyms
Sch32088 ()
mometasone furoate stent, Intersect ENT-2 ()
SCH-32088,mometasone 17-furoate ()
Mometasone Furoate ()
Mometasone furoate component of ryaltris ()
Asmanex Twisthaler ()
Nasonex 24hr allergy ()
SCH-32088 ()
LAS-41002 ()
Lyr-210 ()
NSC-746171 ()
Asmanex hfa ()
Mometasone Furoate Monohydrate ()
Mometasone Furoate Hydrate ()
Nasonex ()
Monovo ()
SCH 32088 ()
LYR210 ()
NSC-760077 ()
Mometasone furoate component of dulera ()
Asmanex ()
Mometasone furoate component of lyr-220 active ()
Sinuva ()
Elocon ()
Mometasone furoate anhydrous ()
LAS41002 ()
Mometasone Furoate-d3 ()
P&D ID
PD012689
CAS
83919-23-7
Tags
available
prodrug
drug
Approved by
EMA
PMDA
FDA
First approval
1987
Drug Status
vet_approved
approved
investigational
Max Phase
4.0
Drug indication
Allergic rhinitis
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of [dexamethasone][A176906]. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action[A176906]. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammation[FDA Label][A176900,A176906,A176918,F4292,F4295].
MOA In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes[A176918]. There is also evidence of inhibition of histamine, leukotrienes, and cytokines[A176918].; ; Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity[A176906]. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of [dexamethasone][A176906]. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus[A176918]. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5)[A176918]. Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB)[A176906,A176918].
INDICATION There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients ≥4 years[FDA Label]. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years, treating nasal polyps in patients ≥18 years, and prophylaxis of seasonal allergic rhinitis in patients ≥12 years[F4292]. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years[F4295].
ROE For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine[FDA Label][F4292].
METABOLISM Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolites[FDA Label][F4292,A176900,A176918]. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate[A176900,A176918,A176879].
ABSORPTION The mean time to peak concentration is 1.0 to 2.5 hours[FDA Label]. Bioavailability has been reported as <1%[FDA Label] but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%[A176918]. The 0.1% ointment may have a bioavailability of 0.7%[F4295].
HALF-LIFE The terminal half life of an inhaled dose is approximately 5 hours[FDA Label] though it has been reported as 5.8 hours by other sources[F4292,A176906].
TOXICITY Overdose with a mometasone furoate inhaler may occur with chronic overuse[FDA Label][F4292]. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoring[FDA Label][F4292].; ; In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humans[FDA Label][F4292,F4295]. The benefits and risks of use should be considered in pregnant patients[F4292,F4295]; ; It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothers[FDA Label][F4292,F4295].; ; Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatment[FDA Label]. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalers[FDA Label].; ; A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoate[FDA Label][F4292,F4295].; ; The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severity[FDA Label][F4292].; ; The effects of mometasone furoate in renal impairment, and across gender and race have not been studied[FDA Label][F4292].
DESCRIPTION Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity. Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo[1]
PRICE 29
DESCRIPTION Glucocorticoid receptor agonist (Tocris Bioactive Compound Library)
DESCRIPTION Mometasone furoate (Sch32088) is a pregnadienediol derivative with anti-allergic and anti-inflammatory properties, used in the management of asthma and allergic rhinitis, as well as a topical treatment for skin disorders. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
17
AdooQ Bioactive Compound Library
A11691
Cayman Chemical Bioactives
21365
33470
ChEMBL Approved Drugs
CHEMBL1161
ChEMBL Drugs
CHEMBL1161
Drug Repurposing Hub
DrugBank
DB14512
DrugBank Approved Drugs
DB14512
DrugCentral
1832
DrugCentral Approved Drugs
1832
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1161
MedChem Express Bioactive Compound Library
HY-13693
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
mometasone-furoate
TargetMol Bioactive Compound Library
T1531
Tocris Bioactive Compound Library
4115
External IDs
52
Properties
(calculated by RDKit )
Molecular Weight
520.14
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
1
cLogP
4.87
TPSA
93.81
Fraction CSP3
0.59
Chiral centers
8.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Glucocorticoid Receptor
NR3C1
Primary Target
Glucocorticoid Receptors
MOA
Agonist
Glucocorticoid Receptor agonist
Indication
corticosteroid-responsive dermatoses
Pathway
Immunology/Inflammation
Vitamin D Related/Nuclear Receptor
Endocrinology/Hormones
Source data